NCT06003101 Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies
| NCT ID | NCT06003101 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Massachusetts General Hospital |
| Condition | Acetabular Labrum Tear |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2023-08-30 |
| Primary Completion | 2027-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 160 participants in total. It began in 2023-08-30 with a primary completion date of 2027-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to assess the effect of PRP/PPP/BMAC application on functional outcomes after hip arthroscopy to address acetabular labral pathologies. The main questions it aims to answer are: 1. Does PRP/PPP/BMAC application improve functional outcomes after hip arthroscopy to address acetabular labral pathologies? 2. Does PRP/PPP/BMAC application reduce the arthritic burden as measured by functional outcomes following hip arthroscopy to address labral pathologies with concomitant PRP/PPP/BMAC application?
Eligibility Criteria
Inclusion Criteria: * Age: \> or equal to 18 years * Clinically indicated for hip arthroscopy (by the study PI) to address a labral pathology * Willingness to participate, amenable to randomization into either treatment arm of the research study, and the ability to understand \& sign the informed consent document Exclusion Criteria: * Non-English speaking (PROM surveys are only validated in English) * Prior same site (i.e., ipsilateral hip) surgery, including but not limited to previous hip arthroscopy, core decompression, or periacetabular osteotomies
Contact & Investigator
Scott D. Martin, MD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT06003101 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acetabular Labrum Tear. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06003101 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 160 participants.
Is NCT06003101 currently recruiting?
Yes, NCT06003101 is actively recruiting participants. Contact the research team at sdmartin@mgh.harvard.edu for enrollment information.
Where is the NCT06003101 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06003101 clinical trial?
NCT06003101 is sponsored by Massachusetts General Hospital. The principal investigator is Scott D. Martin, MD at Massachusetts General Hospital. The trial plans to enroll 160 participants.